FRESENIUS SE & CO. KGAA |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 27.2 EUR | -0.42% |
|
+2.55% | -2.64% |
| Apr. 24 | European Equities Traded in the US as American Depositary Receipts Trend Lower in Wednesday Trading | MT |
| Apr. 24 | FRESENIUS SE : Warburg Research reiterates its Buy rating | ZD |
Presenter SpeechWolfgang Kirsch (Executives)Good morning, ladies and gentlemen. My name is Wol...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Fresenius SE & Co. KGaA specializes in designing, producing, and selling medical drugs, equipment, and devices used in clinical hospitalization and at home. Net sales break down by activity as follows:
- dialysis treatment (46.9%; Fresenius Medical Care): sales of equipment for hemodialysis, pediatric dialysis, peritoneal dialysis, dialysis services, etc.;
- hospital administration and engineering (34.1%; Fresenius Vamed and Fresenius Helios): management of technical facilities and medical equipment, hospital management, design and production of medical equipment for the pharmaceutical sector, etc.;
- perfusion and clinical nutrition (19%; Fresenius Kabi): sales of parenteral and oral nutrition products, perfusion and vascular filling equipment, transfusion materials, generic injectable products, home medical assistance services in the areas of perfusion, nutrition, and oxygen therapy, etc.
Net sales are distributed geographically as follows: Europe (43.8%), North America (39.4%), Asia/Pacific (10.1%), Latin America (5.4%) and Africa (1.3%).
Calendar
2024-05-07
- Q1 2024 Earnings Call
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
BUY
Number of Analysts
16
Last Close Price
27.32
EUR
Average target price
36.28
EUR
Spread / Average Target
+32.80%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.64% | 16.44B | |
| -14.97% | 85.42B | |
| +16.29% | 84.38B | |
| +10.92% | 29.39B | |
| -12.53% | 17.49B | |
| -1.05% | 15.28B | |
| +0.32% | 12.22B | |
| -31.23% | 11.98B | |
| -3.02% | 11.71B | |
| +25.66% | 11.64B |
- Stock Market
- Equities
- FRE Stock
- News Fresenius SE & Co. KGaA
- Transcript : Fresenius SE & Co. KGaA - Shareholder/Analyst Call
